Sweden
· Delayed Price · Currency is SEK · Price in DKKDanCann Pharma Statistics
Total Valuation
DanCann Pharma has a market cap or net worth of SEK 5.70 million. The enterprise value is 5.39 million.
| Market Cap | 5.70M |
| Enterprise Value | 5.39M |
Important Dates
The last earnings date was Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DanCann Pharma has 1.54 billion shares outstanding. The number of shares has increased by 990.03% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.54B |
| Shares Change (YoY) | +990.03% |
| Shares Change (QoQ) | +27.78% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 8.49% |
| Float | 1.54B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| PB Ratio | 0.28 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.06 |
| EV / Sales | 0.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.77 |
Financial Position
The company has a current ratio of 1.26
| Current Ratio | 1.26 |
| Quick Ratio | 0.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.30 |
Financial Efficiency
Return on equity (ROE) is -163.93% and return on invested capital (ROIC) is -95.22%.
| Return on Equity (ROE) | -163.93% |
| Return on Assets (ROA) | -80.64% |
| Return on Capital (ROIC) | -95.22% |
| Revenue Per Employee | 1.01M |
| Profits Per Employee | -7.32M |
| Employee Count | 12 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -91.72% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 38.93 |
| Average Volume (20 Days) | 152,096,249 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DanCann Pharma had revenue of SEK 12.17 million and -87.83 million in losses. Loss per share was -0.07.
| Revenue | 12.17M |
| Gross Profit | -1.92M |
| Operating Income | -81.63M |
| Pretax Income | -84.08M |
| Net Income | -87.83M |
| EBITDA | -76.74M |
| EBIT | -81.63M |
| Loss Per Share | -0.07 |
Balance Sheet
| Cash & Cash Equivalents | 304,900 |
| Total Debt | n/a |
| Net Cash | 304,900 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 20.19M |
| Book Value Per Share | 0.01 |
| Working Capital | 958,691 |
Cash Flow
In the last 12 months, operating cash flow was -7.45 million and capital expenditures 424,737, giving a free cash flow of -7.02 million.
| Operating Cash Flow | -7.45M |
| Capital Expenditures | 424,737 |
| Free Cash Flow | -7.02M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -15.79% |
| Operating Margin | -670.66% |
| Pretax Margin | -690.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DanCann Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -990.03% |
| Shareholder Yield | -990.03% |
| Earnings Yield | -1,932.04% |
| FCF Yield | -123.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DanCann Pharma has an Altman Z-Score of -9.47. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.47 |
| Piotroski F-Score | n/a |